NASDAQ:VERO - Nasdaq - US92332W2044 - Common Stock - Currency: USD
VENUS CONCEPT INC
NASDAQ:VERO (1/30/2025, 8:00:01 PM)
After market: 0.34 -0.01 (-3.44%)0.3521
-0.01 (-1.84%)
The current stock price of VERO is 0.3521 USD. In the past month the price decreased by -2.19%. In the past year, price decreased by -71.83%.
Monday's after hours session: top gainers and losers
TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology...
Enhances future international growth profile with new partners and regulatory certifications in key global aesthetic markets...
TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.58 | 223.42B | ||
ISRG | INTUITIVE SURGICAL INC | 79.15 | 206.65B | ||
BSX | BOSTON SCIENTIFIC CORP | 43.66 | 151.86B | ||
SYK | STRYKER CORP | 32.03 | 148.84B | ||
MDT | MEDTRONIC PLC | 17.52 | 117.96B | ||
BDX | BECTON DICKINSON AND CO | 18.88 | 72.06B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.42 | 43.19B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 21.22 | 40.91B | ||
RMD | RESMED INC | 31.08 | 37.82B | ||
IDXX | IDEXX LABORATORIES INC | 38.72 | 34.72B | ||
DXCM | DEXCOM INC | 51.54 | 34.22B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.93 | 26.36B |
Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. The company is headquartered in Toronto, Ontario and currently employs 304 full-time employees. The company went IPO on 2017-10-12. The firm develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and 10 direct markets. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.
VENUS CONCEPT INC
235 Yorkland Blvd Suite 900
TORONTO ONTARIO M2J 4Y8 CA
CEO: Domenic Serafino
Employees: 304
Company Website: https://www.venusconcept.com/en-uk/
Investor Relations: http://www.ir.venusconcept.com
Phone: 18778488430
The current stock price of VERO is 0.3521 USD.
The exchange symbol of VENUS CONCEPT INC is VERO and it is listed on the Nasdaq exchange.
VERO stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VERO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VERO.
VERO does not pay a dividend.
VERO does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.02).
The outstanding short interest for VERO is 0.83% of its float.
ChartMill assigns a technical rating of 1 / 10 to VERO. When comparing the yearly performance of all stocks, VERO is a bad performer in the overall market: 94.89% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to VERO. VERO may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months VERO reported a non-GAAP Earnings per Share(EPS) of -8.02. The EPS decreased by -15.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -69.38% | ||
ROE | -496.11% | ||
Debt/Equity | 3.4 |
ChartMill assigns a Buy % Consensus number of 48% to VERO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -1.6% and a revenue growth -17.86% for VERO